李少磊, 羅 妍, 王莉華, 李德江
(三峽大學 化學與生命科學學院,湖北 宜昌 443002)
1,3,5-噁二唑類化合物具有抗癌、消炎、止痛、降壓、解痙攣、消水腫,滅菌及殺蟲活性[1,2],而1,3,4-噁唑啉類化合物有殺蟲、殺菌、抗愛滋病毒和抗驚厥等生物活性,其應用前景頗受青睞[3~7]。含氟的化合物也是重要的殺菌和抗真菌劑, 例如氟康唑其抗菌譜廣,毒性低,既可口服又可靜注給藥,具有良好的藥動學特性。
為了尋找更強、更好的殺菌、抗癌活性的化合物,我們設想將對氟苯基和噁二唑環(huán)或噁唑啉環(huán)構筑于同一分子,期望獲得新的具有生物活性的化合物。本文報道對氟苯甲酸甲酯在無水乙醇中與80%水合肼反應,制得對氟苯甲酰肼(1); 1與苯甲醛反應制得對氟苯甲酰腙(2); 2與乙酸酐或丙酸酐反應后再脫水環(huán)化合成了2-苯基-3-乙?;?5-對氟苯基-1,3,4-噁唑啉(3)或2-苯基-3-丙?;?5-對氟苯基-1,3,4-噁唑啉(4, Scheme 1)。1與苯甲酰氯反應制得N-對氟苯甲?;?N′-苯甲酰肼(5); 5在POCl3存在下脫水環(huán)化合成了2-苯基-5-對氟苯基-1,3,4-噁二唑(6, Scheme 1)。新化合物3,4和6的結構經(jīng)1H NMR, IR, MS和元素分析表征。用MTT方法評價了其對HepG-2, A549-1和231-2癌細胞株的體外生長抑制活性。結果表明,3,4和6均具有潛在的體外抑制癌細胞生長活性,其中3的活性最強。
Scheme1
X-4型熔點儀(溫度計未經(jīng)校正);Varian Mercury 400型核磁共振儀(CDCl3為溶劑,TMS為內標);Nicolet Nexus 470型紅外光譜儀(KBr壓片);Finnigan Trace型質譜儀;Vario EL Ⅲ型元素分析儀。
1,2和5參照文獻[8]方法合成;其余所用試劑均為化學純或分析純。
(1) 3和4的合成
在三頸瓶中加入2 650 mg(2.5 mol),乙酸酐12.5 mL,攪拌下回流反應2 h(TLC跟蹤)。冷卻至室溫,抽濾,濾餅用無水乙醇重結晶得白色晶體3610 mg,產率80%, m.p.93℃~94 ℃;1H NMRδ: 2.35(s, 3H, CH3), 7.00~7.13(m, 3H, 2-H, ArH), 7.22~7.824(m, 5H, ArH), 7.87~8.02(m, 2H, ArH); IRν: 3 075, 1 663, 1 606, 1 427, 1 216, 1 154 cm-1; MSm/z: 284(M+, 21%); Anal.calcd for C16H13N2O2F: C 67.59, H 4.61, N 9.85; found C 67.37, H 4.76, N 9.69。
用類似方法合成白色晶體4(用50%丙酮重結晶) 630 mg,產率78%, m.p.85 ℃~87 ℃;1H NMRδ: 1.19(t, 3H, CH3), 2.72(q, 2H, CH2), 7.06~727(m, 3H, 2-H, ArH), 7.36~7.91(m, 5H, ArH), 8.13~8.16(m, 2H, ArH); IRν: 3 046, 1 712, 1 632, 1 606, 1 447, 1 235, 1 104 cm-1; MSm/z: 298(M+, 15%); Anal.calcd for C17H15N2O2F: C 68.44, H 5.07, N 9.39; found C 68.62, H 5.13, N 9.18。
(2)6的合成
在圓底燒瓶中加入51.32 g和POCl310 mL,攪拌下回流反應7 h(TLC跟蹤)。冷卻至室溫,倒入碎冰(100 mL)中攪拌1 h,抽濾,濾餅用水洗滌,無水乙醇重結晶得白色晶體6910 mg,產率81%, m.p.152 ℃~154 ℃;1H NMRδ: 7.22~7.53(m, 2H, ArH), 7.53~7.57(m, 3H, ArH), 8.13~8.17(m, 4H, ArH); IRν: 3 050, 1 611, 1 555, 1 488, 1 139 cm-1; MSm/z: 240(M+, 100%); Anal.calcd for C14H9N2OF: C 69.99, H 3.78, N 11.66; found C 69.83, H 3.67, N 11.79。
以3,4和6作為供試樣品,絲裂霉素(20 μg·mL-1)作為陽性對照組。以DMSO為溶劑配制藥液(1.0×10-2μg·mL-1),用RPMI-1640(Roswell Park Memorial Institute)稀釋到所需濃度。取對數(shù)生長期的肝癌細胞(HepG-2)[或肺癌細胞(A549-1),乳腺癌細胞(231-2)]以每孔6 000個細胞接種于96孔板,培養(yǎng)隔夜后,加入不同濃度藥液。48 h后棄去培養(yǎng)基,每孔加入5 g·L-1的MTT溶液20 μL,繼續(xù)培養(yǎng)4 h,棄去上層清液,每孔加入DMSO 150 μL,輕輕振蕩30 min,用酶標儀在492 nm波長處測其吸光度(A)。按下式計算藥液對癌細胞的抑制率(%),然后以各藥物濃度對數(shù)值對各濃度下的抑制率作線性回歸,從所得劑量-效應方程計算出各供試樣對實驗癌細胞的半數(shù)抑制濃度(IC50/μg·L-1)。
3,4和6的體外抗癌活性測試結果見表1。由表1可見,3,4和6均具一定的體外抗癌活性;其中3與絲裂霉素的抗癌效果相當。3相對于絲裂霉素要便宜很多,因而具有良好的市場前景。
[1] Al Talib, Hasan Tashtoush, Sasakik. A convenient synthesis of alkyl and aryl substituted bis-1,3,4-oxadiazoles[J].Synthetic Communications,1990,20(12):1811-1817.
表 1 3, 4和6的體外抗癌活性測試結果Table 1 The test results of 3, 4 and 6 in vitro anticancer activity
[2] Shaukath Ara Khanum, S Shashikanth. Microwave-assisted synthesis of 2-amino and 2-azetidinonyl 5-(2-benzoyl-phenoxymethyl)-1,3,4-oxadiazoles[J].Heteroatom Chemistry,2004,15(1):37-42.
[3] Michael J Hearn, Phet-Yoon Chanyaputhipong. Preparation and spectroscopic of 3-acyl-1,3,4-oxadiazolines[J].Heterocyclic Chem,1995,32:1647-1649.
[4] Michael J. Hearn, Phet-Yoon Chanyaputhipong. Preparation and spectroscopic of 3-acyl-1,3,4-oxadiazolines[J].Heterocyclic Chem,1995,32:1647-1649.
[5] Shaoyong Ke, Fengyi Liu, Ni Wang,etal. 1,3,4-Oxadiazoline derivatives as novel potential inhibitors targeting chitinbiosynthesis:Design,synthesis and biological evaluation[J].Bioorganic & Medicinal Chemistry Letters,2009,19:332-335.
[6] Shaoyong Ke, Zhong Li, Xuhong Qian. 1,3,4-Oxadiazole-3(2H)-carboxamide derivatives as potential novel class of monoamine oxidase(MAO) inhibitors:Synthesis,evaluation,and role of urea moiety[J].Bioorganic & Medicinal Chemistry,2008,16:17565-7572.
[7] Joshi S D, Vagdevia H M, Vaidya V P,etal. Synthesis of new 4-pyrrol-1-yl benzoic acid hydrazide analogs and some derived oxadiazole, triazole and pyrrole ring systems:A novel class of potential antibacterial and antitubercular agents[J].European Journal of Medicinal Chemistry,2008,43:1989-1996.
[8] 畢秀成,李德江,傅和青. 2-芳基-3-N-丙酰基-5-(3-吡啶基)-1,3,4-噁唑啉類衍生物的合成[J].合成化學,2007,15(7):225-228.